Cholesterol Cardiovascular Diseases
Conditions
Interventions
This is an experimental study with a quantitative, randomized, blinded, placebo-controlled approach, involving collaborators and students from the Regional University of the Northwest of the State of
s health monitoring sector, confirming the sample size. To this end, participants will be divided into three groups of 15 people for each dose, and within each group, three subgroups will be formed to
Sponsors
Universidade Regional do Noroeste do Estado do Rio Grande do Sul
Universidade Regional do Noroeste do Estado do Rio Grande do Sul
Eligibility
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Collaborating individuals from the Regional University of the Northwest of the State of Rio Grande do Sul (UNIJUÍ); who are between 18 and 50 years old; both sexes; those with dyslipidemia
Exclusion criteria
Exclusion criteria: Pregnant women; use cholesterol medications; who do not accept to participate in the research; who do not sign the Free and Informed Consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: Positive effects on the reduction and control of dyslipidemia were expected, through the use of the product developed for oral ingestion, with the analysis of biomarkers.;Outcome found 1: Reduction in total cholesterol | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 2: Through the analysis of biomarkers of oxidative stress, such as: Catalase, Superoxide Dismutase, NP-SH (Non-Protein Sulfhydryls), Tissue Lipoperoxidation, Glutathione Reductase, Glutathione Peroxidase and Carbonylated Proteins, benefits were expected in using the product.;Outcome found 2: Antioxidant effects of beta-glucan were observed, with alterations in tissue lipid peroxidation and NP-SH (non-protein sulfhydryl groups) | — |
Countries
BR
Contacts
Public ContactChristiane Colet
Universidade Regional do Noroeste do Estado do Rio Grande do Sul
Outcome results
None listed